NewLink Genetics

NewLink Genetics Corporation (NewLink) is a biopharmaceutical company focused on discovering, developing and commercializing immunotherapeutic products for cancer treatment. Its portfolio includes both biologic and small-molecule immunotherapy product candidates. Its biologic product candidates are based on its HyperAcute immunotherapy technology, which is designed to stimulate the human immune system. Its small-molecule product candidates are focused on breaking the immune system's tolerance to cancer by inhibiting the indoleamine-(2, 3)-dioxygenase (IDO) pathway. Its lead product candidate algenpantucel-L or HyperAcute Pancreas. HyperAcute Pancreas is being studied in two Phase III clinical trials; one in surgically-resected pancreatic cancer patients that is being performed under a Special Protocol Assessment (SPA) with the United States Food and Drug Administration (FDA) and one in patients with locally advanced pancreatic cancer.
Company Growth (employees)
Type
Public
HQ
Ames, US
Founded
1999
Size (employees)
122 (est)-41%
NewLink Genetics was founded in 1999 and is headquartered in Ames, US

NewLink Genetics Office Locations

NewLink Genetics has offices in Ames, Austin, Devens
Ames, US (HQ)
5100 2503 S Loop Dr
Devens, US
108 94 Jackson Rd
Austin, US
100 2700 Vía Fortuna

NewLink Genetics Metrics

NewLink Genetics Financial Metrics

Revenue (2016)

$35.8 m

Revenue growth (2015-16), %

(48%)

Net income (2016)

($85.2 m)

Market capitalization (21-Mar-2017)

$641.3 m

Closing share price (21-Mar-2017)

$22.4

Cash (31-Dec-2016)

$131.5 m
NewLink Genetics's current market capitalization is $641.3 m.
NewLink Genetics's revenue was reported to be $35.8 m in FY, 2016 which is a 47.8% decrease from the previous period.
FY, 2013FY, 2014FY, 2015FY, 2016

Revenue

$1.1 m$172.6 m$68.5 m$35.8 m

Revenue growth, %

15691%(60%)(48%)

Operating expense total

$147.3 m$55 m$102.1 m$126.5 m

EBIT

($138.8 m)$117.6 m($33.6 m)($90.8 m)

EBIT margin, %

(12702%)68%(49%)(254%)

Interest expense

$33 k$26 k$105 k$22 k

Interest income

$12 k$86 k$78 k$237 k

Income tax expense

($130 k)($14.8 m)($6.7 m)$5.4 m

Net Income

($136.5 m)$102.9 m($40.4 m)($85.2 m)
FY, 2013FY, 2014FY, 2015FY, 2016

Cash

$61.3 m$190.4 m$195.6 m$131.5 m

Accounts Receivable

$1.3 m$3.7 m$5.4 m$24.5 m

Inventories

$5 m$5.9 m

Current Assets

$64 m$230.5 m$208.1 m$167.9 m

PP&E

$6.8 m

Total Assets

$70.6 m$238.1 m$218.5 m$174.7 m

Accounts Payable

$612 k$2.4 m$3.7 m$22.9 m

Current Liabilities

$3.9 m$25 m$14.8 m$37.9 m

Non-Current Liabilities

$8.4 m$9.3 m$7.9 m$7.4 m

Total Liabilities

$12.2 m$34.3 m$22.8 m$45.3 m

Additional Paid-in Capital

$194 m$236.8 m$276.6 m$295.5 m

Retained Earnings

($33.1 m)($80.4 m)($165.5 m)

Total Equity

$58.3 m$203.8 m$195.8 m$129.5 m

Financial Leverage

1.2 x1.2 x1.1 x1.3 x
FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

($31.2 m)$102.9 m($40.4 m)($85.2 m)

Depreciation and Amortization

$891 k$1.1 m$1.6 m$2.1 m

Accounts Receivable

$1.1 m($2.4 m)($1.7 m)($19 m)

Inventories

$3.4 m

Accounts Payable

($359 k)$7.9 m$245 k$24.8 m

Cash From Operating Activities

$61.3 m$109.1 m($24.1 m)($65.9 m)

Purchases of PP&E

($1.4 m)($1.7 m)($4 m)($2.2 m)

Cash From Investing Activities

($141 k)($13.8 m)$6.2 m($66 k)

Short-term Borrowings

($154 k)($158 k)

Interest Paid

$34 k$26 k$105 k$22 k

Income Taxes Paid

$26.4 m$4.8 m$1 m

NewLink Genetics Market Value History

NewLink Genetics Company Life

You may also be interested in